Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case‑control study

Ibrahim,Fawziya Abd Elmaogoud Ragab; Elfeky,Shaymaa Essam; Haroun,Medhat; Ahmed,Mohamed Abd Elrahman; Elnaggar,Mostafa; Ismail,Nada Abd Elfatah; Abd El Moneim,Nadia Ahmed

doi:10.3892/mco.2020.2041

Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case‑control study

Authors:
- Fawziya Abd Elmaogoud Ragab Ibrahim
- Shaymaa Essam Elfeky
- Medhat Haroun
- Mohamed Abd Elrahman Ahmed
- Mostafa Elnaggar
- Nada Abd Elfatah Ismail
- Nadia Ahmed Abd El Moneim
View Affiliations

Affiliations: Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt, Department of Radiation Sciences, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt, Department of Biotechnology, Institute of Graduate Studies and Research, University of Alexandria, Alexandria 21526, Egypt, Department of Clinical Pathology, Medical Military Academy, Alexandria 21615, Egypt, Department of Cancer Management and Research, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt
Published online on: May 5, 2020 https://doi.org/10.3892/mco.2020.2041
Pages: 54-62

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Two single nucleotide polymorphisms (SNPs) of matrix metalloproteinase (MMPs) 3 and 9 are functionally implicated in the progression of various types of cancer, including breast cancer (BC). However, the roles of these SNPs remain controversial. In addition, they also vary between one population and another. Therefore, the present study aimed to investigate the possible association between MMP3‑1171 5A/6A and MMP9‑1562 CT SNPs and the risk of BC among Egyptians, and to elucidate the alteration of MMP3 and MMP9 gene expression in patients with BC. The present case‑control study enrolled 162 patients with BC and 146 control subjects. Restriction fragment length polymorphism‑PCR was performed for analysis of the selected SNPs, gene expression of MMP3 and MMP9 was also assessed in 50 patients and 50 control subjects by reverse transcription‑quantitative PCR. The frequencies of 5A/6A genotype and 5A allele of MMP3 were significantly higher in patients with BC compared with in healthy subjects. On the other hand, the distributions of MMP9 genotypes and alleles were not significantly different among patients and healthy subjects. Compared with healthy subjects, the expression levels of the two genes were found to be upregulated in patients with BC. Therefore, the present study indicated that MMP3‑1171 5A/6A SNP, not MMP9‑1562 C>T SNP may be a risk factor for developing BC among Egyptian females.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO and Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 24:1495–1506. 2015.PubMed/NCBI View Article : Google Scholar
3	Ibrahim AS, Khaled HM, Mikhail NN, Baraka H and Kamel H: Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014(437971)2014.PubMed/NCBI View Article : Google Scholar
4	Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al: Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 45353–361. (361e1-e2)2013.PubMed/NCBI View Article : Google Scholar
5	Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, et al: Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 45392–398. (398e1-e2)2013.PubMed/NCBI View Article : Google Scholar
6	Deng N, Zhou H, Fan H and Yuan Y: Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 8:110635–110649. 2017.PubMed/NCBI View Article : Google Scholar
7	Sternlicht MD, Bissell MJ and Werb Z: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 19:1102–1113. 2000.PubMed/NCBI View Article : Google Scholar
8	Verma S, Kesh K, Gupta A and Swarnakar S: An overview of matrix metalloproteinase 9 polymorphism and gastric cancer risk. Asian Pac J Cancer Prev. 16:7393–7400. 2015.PubMed/NCBI View Article : Google Scholar
9	Toroghi F, Mashayekhi F, Montazeri V, Saedi HS and Zivar S: Association of MMP-9 promoter polymorphism and breast cancer among Iranian patients. Eur J Oncol. 22:38–42. 2017.
10	Liu D, Guo H, Li Y, Xu X, Yang K and Bai Y: Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: A meta-analysis. PLoS One. 7(e31251)2012.PubMed/NCBI View Article : Google Scholar
11	Li X, Qu L, Zhong Y, Zhao Y, Chen H and Daru L: Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: A meta-analysis. J Cancer Res Clin Oncol. 139:1433–1447. 2013.PubMed/NCBI View Article : Google Scholar
12	Okamoto K, Ishida C, Ikebuchi Y, Mandai M, Mimura K, Murawaki Y and Yuasa I: The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med. 49:887–895. 2010.PubMed/NCBI View Article : Google Scholar
13	Motovali-Bashi M, Hojati Z and Hajihoseiny S: The role of matrix metalloproteinase-3 functional 5A/6A promoter polymorphism in tumor cell progression and metastasis of breast cancer. Iran J Biotechnol. 6:45–9. 2008.
14	Sadeghi M, Motovali-bashi M and Hojati Z: MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. Int J Integrat Biol. 6:33–37. 2009.PubMed/NCBI View Article : Google Scholar
15	Gencer S, Cebeci A and Irmak-Yazicioglu MB: Matrix metalloproteinase gene expressions might be oxidative stress targets in gastric cancer cell lines. Chin J Cancer Res. 25:322–333. 2013.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Chouchane L, Boussen H and Sastry KS: Breast cancer in Arab populations: Molecular characteristics and disease management implications. Lancet Oncol. 14(e417-e424)2013.PubMed/NCBI View Article : Google Scholar
18	Blons H, Gad S, Zinzindohoué F, Manière I, Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O and Laurent-Puig P: Matrix metalloproteinase 3 polymorphism: A predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 10:2594–2599. 2004.PubMed/NCBI View Article : Google Scholar
19	Ding C, Chen X, Zhang PT, Huang JP, Xu Y, Chen N and Zhong LJ: Matrix Metalloproteinase-3-1171 5A/6A Polymorphism (rs35068180) is Associated with Risk of Periodontitis. Sci Rep. 5(11667)2015.PubMed/NCBI View Article : Google Scholar
20	Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P and Försti A: Promoter polymorphisms in matrix metalloproteinases and their inhibitors: Few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 103:61–69. 2007.PubMed/NCBI View Article : Google Scholar
21	Srivastava P, Gangwar R, Kapoor R and Mittal RD: Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers. 29:37–46. 2010.PubMed/NCBI View Article : Google Scholar
22	Padala C, Tupurani MA, Puranam K, Gantala S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi RK, Kupsal K, et al: Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 12(e0184448)2017.PubMed/NCBI View Article : Google Scholar
23	Abdraboh NR and Bayoumi FA: Gene polymorphism of matrix metalloproteinases 3 and 9 in breast cancer. Gene Rep. 5:151–156. 2016. View Article : Google Scholar
24	Chiranjeevi P, Spurthi KM, Rani NS, Kumar GR, Aiyengar TM, Saraswati M, Srilatha G, Kumar GK, Sinha S, Kumari CS, et al: Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer. Tumour Biol. 35:1351–1356. 2014.PubMed/NCBI View Article : Google Scholar
25	Chaudhary AK, Pandya S, Mehrotra R and Singh M and Singh M: Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 16:577–586. 2011.
26	Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J and Blasiak J: Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 95:65–72. 2006.PubMed/NCBI View Article : Google Scholar
27	Fu F, Wang C, Chen LM, Huang M and Huang HG: The influence of functional polymorphisms in matrix metalloproteinase 9 on survival of breast cancer patients in a Chinese population. DNA Cell Biol. 32:274–282. 2013.PubMed/NCBI View Article : Google Scholar
28	Amălinei C, Căruntu ID, Giuşcă SE and Bălan RA: Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 51:215–228. 2010.PubMed/NCBI
29	Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Zhang ZF, Shan Q, Hu B, Li MQ and Cheng W: CERS2 suppresses tumor cell invasion and is associated with decreased V-ATPase and MMP-2/MMP-9 activities in breast cancer. J Cell Biochem. 116:502–513. 2015.PubMed/NCBI View Article : Google Scholar
30	Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, et al: MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. 7:18531–18540. 2016.PubMed/NCBI View Article : Google Scholar
31	Jafari M, Pirouzi A, Mohsenzadeh M, Kusari AA and Hajihosseini S: Association of MMP 9-1562C/T single nucleotide polymorphism with the susceptibility to lung cancer disease in South Iranian population. J Med Med Res. 4:2494–2502. 2014.PubMed/NCBI View Article : Google Scholar
32	McColgan P and Sharma P: Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer. 125:1473–1478. 2009.PubMed/NCBI View Article : Google Scholar
33	Yang X, Hu JW, Qiu MT, Li M, Yin R, Wang J, Xu L and Zhang Q: Association of matrix metalloproteinase-3-1171 (5A>6A) polymorphism with cancer risk: A meta-analysis of 41 studies. PLoS One. 9(e87562)2014.PubMed/NCBI View Article : Google Scholar
34	Fanjul-Fernández M, Folgueras AR, Cabrera S and López-Otín C: Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 1803:3–19. 2010.PubMed/NCBI View Article : Google Scholar
35	Medley TL, Kingwell BA, Gatzka CD, Pillay P and Cole TJ: Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 92:1254–1261. 2003.PubMed/NCBI View Article : Google Scholar
36	Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, et al: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 99:1788–1794. 1999.PubMed/NCBI View Article : Google Scholar
37	Youssef NS and Hakim SA: Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol. 9(136)2014.PubMed/NCBI View Article : Google Scholar
38	Yousef EM, Tahir MR, St-Pierre Y and Gaboury LA: MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 14(609)2014.
39	Jormsjö S, Whatling C, Walter DH, Zeiher AM, Hamsten A and Eriksson P: Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 21:1834–1839. 2001.PubMed/NCBI View Article : Google Scholar
40	Rahimi Z, Yari K and Rahimi Z: Matrix metalloproteinase-9-1562T allele and its combination with MMP-2-735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 16:1175–1179. 2015.PubMed/NCBI View Article : Google Scholar
41	Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N and Maruo T: Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig. 13:523–529. 2006.PubMed/NCBI View Article : Google Scholar
42	Song J, Su H, Zhou YY and Guo LL: Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: A meta-analysis. Asian Pac J Cancer Prev. 14:1615–1621. 2013.PubMed/NCBI View Article : Google Scholar